genedrive CEO: NHS adoption and global expansion drive point-of-care testing push

genedrive PLC (AIM:GDR) CEO Dr Gino Miele spoke with Proactive's Stephen Gunnion about the diagnostic company's progress in rapid point-of-care genetic testing, growing NHS adoption and international expansion plans. Miele explained that Manchester-based genedrive has developed two CE-IVD-approved, NICE-recommended tests to help clinicians make safer prescribing decisions in emergency and acute care. The MT-RNR1 test identifies newborns at risk of irreversible hearing loss from aminoglycoside antibiotics, while the CYP2C19 test identifies stroke patients unlikely to respond well to the antiplatelet drug clopidogrel. On MT-RNR1, Miele highlighted completion of patient recruitment for the PALOH UK programme, covering more than 6,000 babies across 14 hospitals in all four UK nations, with clinical analysis under way and publication expected next month ahead of further NICE guidance in July 2027. "This will be a really important commercial catalyst for the business, alongside NHS England procurement routes as well," he said. He discussed international ambitions, including a memorandum of understanding with Saudi Arabia's Ministry of Health, routine clinical use at the National Guard hospital there, implementation at Erasmus MC in the Netherlands, and plans around FDA routes in the US. Miele also highlighted genedrive's collaboration with Thermo Fisher to develop a laboratory-format version of the CYP2C19 test, complementing its existing point-of-care offering. Longer term, genedrive is targeting further international expansion, additional clinical indications, and recurring consumables revenue as its tests become embedded in routine care pathways. Visit Proactive's YouTube channel for more interviews and market updates. Give the video a like, subscribe to the channel and enable notifications so you don't miss future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #genedrive #GDR #GeneticTesting #Pharmacogenetics #Diagnostics #PointOfCareTesting #NHS #NICE #MTRNR1 #CYP2C19 #Stroke #Healthcare #MedTech #MolecularDiagnostics #PersonalisedMedicine #ThermoFisher #Investing #Proactive